Table 2

Effect of intervention at 3 months follow-up

 Usual careHomeBetween groups comparison95% CI
Δ 0–3  months95% CIΔ 0–3  months95% CI
Exercise capacity
 6MWT, m10.1−23.6, 43.936.3−0.9, 73.626.2−24.1 to  76.5
 STS0.9−0.8, 2.61.0−0.8, 2.80.1−2.3 to 2.6
Clinical status
 Systolic blood pressure, mm Hg2.0−8.4, 12.4−12.9−24.2, −1.6*−14.9−30.2 to 0.5
 Diastolic blood pressure, mm Hg4.1−2.2, 10.5−1.5−8.4, 5.4−5.7−15.0 to 3.7
 BMI, kg/m20.1−1.3, 1.5−0.5−2.1, 1.1−0.6−2.7 to 1.5
 Waist–hip ratio−0.01−0.03, 0.01−0.01−0.03, 0.010−0.03 to 0.03
Laboratory values
 Total cholesterol, mmol/l−0.2−0.6, 0.2−0.1−0.5, 0.40.1−0.5, 0.7
 HDL cholesterol, mmol/l0.1−0.01, 0.20.1−0.1, 0.2−0.04−0.2, 0.1
 LDL cholesterol, mmol/l−0.2−0.5, 0.1−0.1−0.5, 0.30.1−0.4 to 0.6
 Cholesterol/HDL ratio−0.4−0.7, 0−0.3−0.7, 0.10.1−0.5 to 0.7
HRQoL, anxiety and depression
 HADS anxiety score−0.9−2.3, 0.5−1.2−2.7, 0.6−0.3−2.4 to 1.9
 HADS depression score−1.1−2.6, 0.4−1.0−2.7, 0.60.1−2.2 to 2.3
 SF-12 PCS2.7−1.4, 6.8−0.45.1, 4.3−3.1−9.4 to 3.1
 SF-12 MCS3.5−0.9, 7.92.4−2.6, 7.5−1.0−7.7 to 5.6
  • All data are adjusted for age and gender.

  • *p<0.05.

  • BMI, body mass index; HADS, hospital anxiety and depression score; HDL, high density lipoprotein; HRQoL, health-related quality of lifeLDL, low density lipoprotein; MCS, mental component summary scale of SF-12; PCS, physical component summary scale of SF-12; STS, sit to stand test; 6MWT, 6 min walk test.